Patents by Inventor Brian C. Austad
Brian C. Austad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11807629Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: GrantFiled: July 1, 2021Date of Patent: November 7, 2023Assignee: Karyopharm Therapeutics Inc.Inventors: Brian C. Austad, David G. Roe
-
Patent number: 11753401Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: GrantFiled: April 5, 2023Date of Patent: September 12, 2023Assignee: Karyopharm Therapeutics Inc.Inventors: Brian C. Austad, David G. Roe
-
Patent number: 11746102Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: GrantFiled: April 7, 2023Date of Patent: September 5, 2023Assignee: Karyopharm Therapeutics Inc.Inventors: Brian C. Austad, David G. Roe
-
Publication number: 20230242516Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: ApplicationFiled: April 5, 2023Publication date: August 3, 2023Inventors: Brian C. Austad, David G. Roe
-
Publication number: 20230242517Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: ApplicationFiled: April 7, 2023Publication date: August 3, 2023Inventors: Brian C. Austad, David G. Roe
-
Publication number: 20220242832Abstract: The present invention provides an improved process for preparation of the (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylic acid (referred to as compound of the structural formula (III)), which is a useful key intermediate for the synthesis of Selinexor ((Z)-3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide). The process comprises reaction of the compound of the structural formula (I) (as described herein) with the compound of the structural formula (II) (as described herein) in the presence of a catalyst, an organic base and an ether-containing solvent. The subsequent hydrolysis of the formed compound of the structural formula (IIIa) (as described herein) is performed without isolation of the compound of the structural formula (IIIa), providing compound of the structural formula (III) in high yield and stereoselectivity.Type: ApplicationFiled: May 1, 2020Publication date: August 4, 2022Inventors: Brian C. Austad, David G. Roe
-
Publication number: 20220135545Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: ApplicationFiled: July 1, 2021Publication date: May 5, 2022Inventors: Brian C. Austad, David G. Roe
-
Patent number: 11078190Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: GrantFiled: November 11, 2019Date of Patent: August 3, 2021Assignee: Karyopharm Therapeutics Inc.Inventors: Brian C. Austad, David G. Roe
-
Publication number: 20200283419Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: ApplicationFiled: November 11, 2019Publication date: September 10, 2020Inventors: Brian C. Austad, David G. Roe
-
Patent number: 10519139Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: GrantFiled: August 14, 2015Date of Patent: December 31, 2019Assignee: Karyopharm Therapeutics Inc.Inventors: Brian C. Austad, David G. Roe
-
Publication number: 20180244700Abstract: The present invention provides fatty acid amide hydrolase inhibitors, solid forms thereof, compositions thereof, and methods of making and using the same.Type: ApplicationFiled: April 23, 2018Publication date: August 30, 2018Inventors: Brian C. Austad, Louis Grenier, Michael J. Grogan, Tao Liu, Priscilla L. White, Theodore A. Martinot, Lin-Chen Yu
-
Publication number: 20180215733Abstract: The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.Type: ApplicationFiled: August 14, 2015Publication date: August 2, 2018Inventors: Brian C. Austad, David G. Roe
-
Patent number: 9951089Abstract: The present invention provides fatty acid amide hydrolase inhibitors, solid forms thereof, compositions thereof, and methods of making and using the same.Type: GrantFiled: February 25, 2015Date of Patent: April 24, 2018Assignee: Infinity Pharmaceuticals, Inc.Inventors: Brian C. Austad, Louis Grenier, Michael J. Grogan, Tao Liu, Priscilla L. White, Theodore A. Martinot, Lin-Chen Yu
-
Patent number: 9879025Abstract: Provided herein is a process for the transfer-hydrogenation of ketone analogs of members of the jervine type of Veratrum alkaloids, such as cyclopamine. Also provided herein are novel ruthenium transfer-hydrogenation catalysts.Type: GrantFiled: June 23, 2016Date of Patent: January 30, 2018Assignee: Infinity Pharmaceuticals, Inc.Inventors: Daniel G. Genov, Brian C. Austad, Brian H. White
-
Patent number: 9879293Abstract: The invention relates to the preparation of amino-cyclopamines by the enzymatic transamination of a corresponding keto-cyclopamines in the presence of a cofactor and an amino donor.Type: GrantFiled: February 25, 2016Date of Patent: January 30, 2018Assignee: Infinity Pharmaceuticals, Inc.Inventors: Brian C. Austad, Adilah Bahadoor, Jitendra D. Belani, Somarajannair Janardanannair, Sheldon L. Wallerstein, Gregg F. Keaney, Priscilla L. White, Charles W. Johannes
-
Publication number: 20170029433Abstract: Provided herein is a process for the transfer-hydrogenation of ketone analogs of members of the jervine type of Veratrum alkaloids, such as cyclopamine. Also provided herein are novel ruthenium transfer-hydrogenation catalysts.Type: ApplicationFiled: June 23, 2016Publication date: February 2, 2017Inventors: Daniel G. Genov, Brian C. Austad, Brian H. White
-
Patent number: 9394313Abstract: Provided herein is a process for the transfer-hydrogenation of ketone analogs of members of the jervine type of Veratrum alkaloids, such as cyclopamine. Also provided herein are novel ruthenium transfer-hydrogenation catalysts.Type: GrantFiled: September 14, 2011Date of Patent: July 19, 2016Assignee: Infinity Pharmaceuticals, Inc.Inventors: Daniel G. Genov, Brian C. Austad, Brian H. White
-
Patent number: 9376447Abstract: Provided herein is a process for the transfer-hydrogenation of ketone analogs of members of the jervine type of Veratrum alkaloids, such as cyclopamine. Also provided herein are novel ruthenium transfer-hydrogenation catalysts.Type: GrantFiled: September 14, 2011Date of Patent: June 28, 2016Assignee: Infinity Pharmaceuticals, Inc.Inventors: Daniel G. Genov, Brian C. Austad, Brian H. White
-
Publication number: 20160177354Abstract: Provided are processes for the synthesis of amino analogues from ketone starting materials.Type: ApplicationFiled: February 25, 2016Publication date: June 23, 2016Inventors: Brian C. Austad, Adilah Bahadoor, Jitendra D. Belani, Somarajannair Janardanannair, Sheldon L. Wallerstein, Gregg F. Keaney, Priscilla L. White, Charles W. Johannes
-
Patent number: 9238672Abstract: The invention is directed to a method to reduce a C—C double bond of an enone of a steroidal compound to produce a mixture of ? ketone product and ? ketone product, comprising treating a solution or suspension of the steroidal compound in a solvent with hydrogen gas in the presence of a catalyst and a substituted pyridine.Type: GrantFiled: May 2, 2014Date of Patent: January 19, 2016Assignee: Infinity Pharmaceuticals, Inc.Inventors: Brian C. Austad, Andre Lescarbeau, Lin-Chen Yu